296
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Emerging Invasive Fungal Infections: Clinical Features and Controversies in Diagnosis and Treatment Processes

& ORCID Icon
Pages 607-615 | Published online: 20 Feb 2020

References

  • Fisher MC, Henk DA, Briggs CJ, et al. Emerging fungal threats to animal, plant and ecosystem health. Nature. 2012;484:186–194. doi:10.1038/nature1094722498624
  • Cho SH, Yu YB, Park JS, Yook KD, Kim YK. Epidemiological characterization of imported systemic mycoses occurred in Korea. Osong Public Health Res Perspect. 2018;9:255–260. doi:10.24171/j.phrp.2018.9.5.0730402381
  • Tarka P, Nitsch-Osuch A, Gorynski P, Tyszko P, Bogdan M, Kanecki K. Epidemiology of pulmonary aspergillosis in hospitalized patients in poland during 2009–2016. Adv Exp Med Biol. 2019;1160:73–80.30919263
  • Hoffmann-Santos HD, Paula CR, Yamamoto AC, Tadano T, Hahn RC. Six-year trend analysis of nosocomial candidemia and risk factors in two intensive care hospitals in Mato Grosso, midwest region of Brazil. Mycopathologia. 2013;176:409–415. doi:10.1007/s11046-013-9705-524113801
  • Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. Epidemiology and clinical features of invasive fungal infection in a US health care network. Open Forum Infect Dis. 2018;5:ofy187. doi:10.1093/ofid/ofy18730151412
  • Dounia B, Olivier L, Yann LS, et al. Population-based analysis of invasive fungal infections, France, 2001–2010. Emerg Infect Dis. 2014;20:1149–1155. doi:10.3201/eid2007.14008724960557
  • Peng L, Xu Z, Huo Z, Long R, Ma L. New insights into the clinical characteristics and prognostic factors of pulmonary fungal infections from a retrospective study in Southwestern China. Infect Drug Resist. 2018;11:307–315. doi:10.2147/IDR29551904
  • Rotjanapan P, Chen YC, Chakrabarti A, et al. Epidemiology and clinical characteristics of invasive mould infections: a multicenter, retrospective analysis in five Asian countries. Med Mycol. 2018;56:186–196. doi:10.1093/mmy/myx02928525619
  • Anugulruengkitt S, Trinavarat P, Chantranuwat P, Sritippayawan S, Pancharoen C, Thanyawee P. Clinical features and survival outcomes of invasive aspergillosis in pediatric patients at a medical school in Thailand. J Med Assoc Thai. 2016;99:150–158.27249894
  • Fracchiolla NS, Sciumè M, Orofino N, et al. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: results from a single-centre study. PLoS One. 2019;14:e0216715. doi:10.1371/journal.pone.021671531071175
  • Dichtl K, Seybold U, Wagener J. Serological biomarkers of candidemia: a retrospective evaluation of three assays. Infection. 2019;47:217–224. doi:10.1007/s15010-018-1224-330264200
  • Pini P, Bettua C, Orsi CF, et al. Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. Infection. 2016;44:223–233. doi:10.1007/s15010-015-0849-826475482
  • Furfaro E, Giacobbe DR, Del Bono V, et al. Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. Mycoses. 2018;61:650–655. doi:10.1111/myc.2018.61.issue-929693758
  • Tong T, Shen J, Xu Y. Serum galactomannan for diagnosing invasive aspergillosis in pediatric patients: a meta-analysis. Microb Pathog. 2018;118:347–356. doi:10.1016/j.micpath.2018.03.05929614368
  • van Paassen J, Russcher A, In ‘t Veld-van Wingerden AW, Verweij PE, Kuijper EJ. Emerging aspergillosis by azole-resistant aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. Euro Surveill. 2016;21:1–9. doi:10.2807/1560-7917.ES.2016.21.30.30300
  • Ruhnke M, Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol. 2016;7:345–359. doi:10.1177/204062071665638127904738
  • De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Researchand Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821. doi:10.1086/58866018462102
  • Rodrigues CF, Rodrigues ME, Henriques M, Candida SP. Infections in patients with diabetes mellitus. J Clin Med. 2019;8:1–41. doi:10.3390/jcm8010076
  • Cohen Atsmoni S, Brener A, Roth Y. Diabetes in the practice of otolaryngology. Diabetes Metab Syndr. 2019;13:1141–1150. doi:10.1016/j.dsx.2019.01.00631336457
  • Rieger H, Lustig D, Barlow S, et al. Applicability of the EORTC/MSG criteria for IFD in clinical practice. Ann Hematol. 2015;94:847–855. doi:10.1007/s00277-014-2282-y25544029
  • Nucci F, Nouér SA, Capone D, Nucci M. Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis. Clin Microbiol Infect. 2018;24:1105.e1–1105.e4. doi:10.1016/j.cmi.2018.05.006
  • Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52:1144–1155. doi:10.1093/cid/cir12221467021
  • Brook O, Guralnik L, Hardak E, et al. Radiological findings of early invasive pulmonary aspergillosis in immune-compromised patients. Hematol Oncol. 2009;27:102–106. doi:10.1002/hon.v27:219294624
  • Brodoefel H, Vogel M, Hebart H, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. AJR Am J Roentgenol. 2006;187:404–413. doi:10.2214/AJR.05.051316861545
  • Angebault C, Lanternier F, Dalle F, et al. Prospective evaluation of serum β-glucan testing in patients with probable or proven fungal diseases. Open Forum Infect Dis. 2016;3:ofw128. doi:10.1093/ofid/ofw12827419189
  • Shourian M, Qureshi ST. Resistance and tolerance to cryptococcal infection: an intricate balance that controls the development of disease. Front Immunol. 2019;10:66. doi:10.3389/fimmu.2019.0006630761136
  • Kobayashi S, Soyama A, Takatsuki M, et al. Relationship between immune function recovery and infectious complications in patients following living donor liver transplantation. Hepatol Res. 2016;46:908–915. doi:10.1111/hepr.v46.926667109
  • Jones TM, Drew RH, Wilson DT, Sarubbi C, Anderson DJ. Impact of automatic infectious diseases consultation on the management of fungemia at a large academic medical center. Am J Health Syst Pharm. 2017;74:1997–2003. doi:10.2146/ajhp17011329167141
  • Moghnieh R, Alothman AF, Althaqafi AO, et al. Epidemiology and outcome of invasive fungal infections and methicillin-resistant staphylococcus aureus (MRSA) pneumonia and complicated skin and soft tissue infections(cSSTI) in Lebanon and Saudi Arabia. J Infect Public Health. 2017;10:849–854. doi:10.1016/j.jiph.2017.01.01328487208
  • Aljeboori Z, Gorelik A, Jenkins E, McFarlane T, Darvall J. Risk factors for candidaemia and their cumulative effect over time in a cohort of critically ill, non-neutropenic patients. Crit Care Resusc. 2018;20:313–319.30482139
  • Hay R, Denning DW, Bonifaz A, et al. The diagnosis of fungal neglected tropical diseases (fungal NTDs) and the role of investigation and laboratory tests: an expert consensus report. Trop Med Infect Dis. 2019;4:E122. doi:10.3390/tropicalmed404012231554262
  • Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405–e421. doi:10.1016/S1473-3099(19)30312-331699664